京都大学医学部附属病院 放射線治療科

menu

業績集 2009

2011 | 2010 |
2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993

1. Harada H, Itasaka S, Kizaka-Kondoh S, et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem. Feb 2009;284(8):5332-5342.

2. Harada H, Itasaka S, Zhu Y, et al. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer. Mar 2009;100(5):747-757.

3. Hirata N, Fujisawa Y, Tanabe K, Harada H, Hiraoka M, Nishimoto S. Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics. Org Biomol Chem. Feb 2009;7(4):651-654.

4. Kizaka-Kondoh S, Itasaka S, Zeng L, et al. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res. May 2009;15(10):3433-3441.

5. Kizaka-Kondoh S, Tanaka S, Harada H, Hiraoka M. The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev. Jul 2009;61(7-8):623-632.

6. Kudo T, Ueda M, Kuge Y, et al. Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells. J Nucl Med. Jun 2009;50(6):942-949.

7. Makino A, Kizaka-Kondoh S, Yamahara R, et al. Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(L-lactic acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. Biomaterials. Oct 2009;30(28):5156-5160.

8. Matsugi K, Narita Y, Sawada A, et al. Measurement of interfraction variations in position and size of target volumes in stereotactic body radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. Oct 2009;75(2):543-548.

9. Miki K, Kuramochi Y, Oride K, et al. Ring-opening metathesis polymerization-based synthesis of ICG-containing amphiphilic triblock copolymers for in vivo tumor imaging. Bioconjug Chem. Mar 2009;20(3):511-517.

10. Mitsumori M, Hiraoka M, Inaji H, et al. Impact of radiation therapy on breast-conserving therapy for breast cancer in Japanese women: a retrospective analyses of multi-institutional experience. Kansai Breast Cancer Radiation Therapy Study Group. Oncol Rep. Jun 2009;21(6):1461-1466.

11. Miyabe Y, Narita Y, Mizowaki T, et al. New algorithm to simulate organ movement and deformation for four-dimensional dose calculation based on a three-dimensional CT and fluoroscopy of the thorax. Med Phys. Oct 2009;36(10):4328-4339.

12. Nagata Y, Hiraoka M, Mizowaki T, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. Oct 2009;75(2):343-347.

13. Nakamura M, Narita Y, Matsuo Y, et al. Effect of audio coaching on correlation of abdominal displacement with lung tumor motion. Int J Radiat Oncol Biol Phys. Oct 2009;75(2):558-563.

14. Nakamura M, Narita Y, Sawada A, et al. Impact of motion velocity on four-dimensional target volumes: a phantom study. Med Phys. May 2009;36(5):1610-1617.

15. Nishimura Y, Mitsumori M, Hiraoka M, et al. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radiother Oncol. Aug 2009;92(2):260-265.

16. Okubo K, Sonobe M, Fujinaga T, et al. Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg. Nov 2009;57(11):585-590.

17. Ou G, Itasaka S, Zeng L, et al. Usefulness of HIF-1 imaging for determining optimal timing of combining bevacizumab and radiotherapy. Int J Radiat Oncol Biol Phys. Oct 2009;75(2):463-467.

18. Sakamoto T, Oya N, Shibuya K, Nagata Y, Hiraoka M. Dose-response relationship and dose optimization in radiotherapy of postoperative keloids. Radiother Oncol. May 2009;91(2):271-276.

19. Takayama K, Mizowaki T, Kokubo M, et al. Initial validations for pursuing irradiation using a gimbals tracking system. Radiother Oncol. Oct 2009;93(1):45-49.

20. Tanabe K, Harada H, Narazaki M, et al. Monitoring of biological one-electron reduction by (19)F NMR using hypoxia selective activation of an (19)F-labeled indolequinone derivative. J Am Chem Soc. Nov 2009;131(44):15982-15983.